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1. In t roduct ion  
1.1. Discovery and history of the first defect in muscle 
glycolysis 
In 1951, Dr. Brian McArdle reported physiological 
studies of a patient who presented with an 'exercise intol- 
erance' [1]: "For as long as the patient could remember, 
light exercise of any muscle had always led to pain in the 
muscle and, if the exercise were continued, to weakness 
and stiffness." [1] 
In contrast to a normal individual, this patient failed to 
produce a rise in blood lactate in response to ischaemic 
forearm exercise. This suggested that there was a block in 
the glycolytic pathway preventing the breakdown of glyco- 
gen to lactate. It was inferred that skeletal muscle alone 
was affected because the normal hyperglycaemic response 
to adrenaline indicated that liver glycogen was broken 
down to glucose. Additionally, normal glycolysis was seen 
in blood cells [1]. 
1.2. Identification of the enzyme defect 
It was not until 8 years later that the defect in glycolysis 
was identified [2,3]. The alleviation of the symptoms of 
this disorder by glucose suggested that the metabolic block 
occurred early in the glycolytic pathway. This was subse- 
quently confirmed by the absence of glycogen phospho- 
rylase activity in powdered muscle from a patient and 
similarly, by a lack of histochemical staining for activity in 
a muscle biopsy [2]. In another study, the addition of 
crystalline phosphorylase to a muscle homogenate from an 
affected individual resulted in a 3-fold increase in lactate 
production, whereas no lactate was generated in the ab- 
sence of exogenous phosphorylase [3]. McArdle's disease 
was thus identified as a lack of muscle glycogen phospho- 
rylase. It has subsequently been classified as Glycogen 
Storage Disease Type V (GSD V). 
1.3. Glycogen phosphorylase 
Glycogen phosphorylase (1, 4-a-D-glucan: orthophos- 
phate a-D-glucosyltransferase, E.C. 2.4.1.1) catalyses the 
phosphorolytic cleavage of glycogen to glucose-l-phos- 
phate at a-l,  4-glycosidic linkages. This glucose-l-phos- 
phate enters the glycolytic pathway to generate ATP with 
the concomitant formation of pyruvate or lactate. How- 
ever, glycogen phosphorylase cannot completely degrade 
glycogen to its constituent glucose units and a second 
enzyme, debrancher enzyme, is required for the cleavage 
of a-1, 6-glycosidic linkages which form the branch points 
in the glycogen molecule. The combined action of these 
enzymes results in approx. 93% glucose-l-phosphate nd 
7% glucose. 
Isozymic forms of glycogen phosphorylase 
Glycogen phosphorylase has three isozymic forms: these 
are known as the muscle, liver and brain isozymes. The 
muscle form has been assigned to the long arm of chromo- 
some 11 by high resolution chromosome sorting and DNA 
spot-blot analysis [4]. The liver form is encoded on chro- 
mosome 14 [5] and the brain form maps to chromosome 20 
and to an homologous equence on chromosome 10 al- 
though it is not known whether the latter is an expressed 
gene or a pseudogene [6]. There is a high degree of 
homology between the amino acid sequences of the three 
isozymes of glycogen phosphorylase [6] and in particular, 
residues involved in the activity of these enzymes are 
highly conserved [7]. This homology at the amino acid 
level is reflected in the nucleotide sequences. However, 
both the amino acid and nucleotide sequences of the 
muscle and brain forms show greater similarity to each 
other than to the liver sequences [6]. 
Although the three isozymes of glycogen phosphorylase 
are highly conserved, each is generally more similar to its 
corresponding isozyme in another species than to the other 
isozymes in the same species [8] and each has a distinct 
physiological role. The muscle isozyme provides ATP for 
muscle contraction whereas the liver form has a homeo- 
static function in the regulation of glucose release from 
hepatic glycogen stores. The brain isozyme is thought o 
provide an emergency supply of glucose during periods of 
anoxia or hypoglycaemia [8]. As their different functions 
would imply, isozymic expression of phosphorylase is
tissue-specific and the brain, liver and muscle isozymes are 
the major forms expressed in the brain, liver and skeletal 
muscle, respectively. Expression in other tissues varies 
between species but in man, the liver form predominates; 
the muscle isozyme is found only in skeletal muscle, heart 
and possibly as a hybrid in brain [9]. It is thought hat the 
brain isozyme is the foetal form of phosphorylase and that 
this is completely or partially replaced uring development 
by the liver and muscle isozymes. This isozyme-switching 
during development is seen in rats [10] and in human 
skeletal muscle [11]. However, northern blot analysis of 
phosphorylase mRNA from a 24 week old human foetal 
liver indicated that the liver transcript predominated in this 
tissue and only low levels of brain mRNA were seen [6]. 
Activation of muscle glycogen phosphorylase 
Glycogen phosphorylase exists as a dimer of identical 
97 kDa subunits. There are two forms of glycogen phos- 
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phorylase: phosphorylase a (higher activity) and phospho- 
rylase b (lower activity) and conversion from b to a can 
be achieved by phosphorylation of Ser-14 [12,13]. 
Phosphorylation f the muscle isozyme is under neural and 
hormonal control. Neural control is mediated by calcium 
flux via calmodulin. Calcium ions released from the sarco- 
plasmic reticulum, upon initiation of muscle contraction, 
bind to the calmodulin y-subunit of phosphorylase kinase 
thus activating it. This enzyme phosphorylates glycogen 
phosphorylase r sulting in more of the high-activity phos- 
phorylase a and hence, glycogen breakdown is induced. 
Hormonal control of glycogen phosphorylase activity is 
mediated via the glycogenolytic cascade in response to 
adrenaline which activates the cAMP-dependent protein 
kinase. This enzyme activates phosphorylase kinase by 
phosphorylation a d this in turn results in an increase in 
phosphorylase a.
Glycogen phosphorylase is also a complex allosteric 
enzyme with two conformers: an active 'R' state and an 
inactive 'T' state and interconversion between these two 
states is via phosphorylation or binding of allosteric lig- 
ands at distinct sites on the enzyme. The muscle isozyme 
can be activated to 80% of its full activation capacity by 
AMP [8]. The phosphorylation site and the AMP binding 
site are in close proximity in the three-dimensional struc- 
ture of the rabbit muscle isozyme and may activate the 
enzyme in the same way. Thus, the muscle isozyme is 
sensitive to both external signals and to changes in the 
concentrations of intracellular ligands which indicate the 
energy balance within the cell. 
Pyridoxal 5' phosphate 
Each subunit of the phosphorylase dimer binds, in a 
tight complex, one molecule of the cofactor pyridoxal-5'- 
phosphate [14] to an active site lysine residue (Lys-680 in 
rabbit muscle phosphorylase) via a Schiff base. The cofac- 
tor is known to play a role in catalysis and although the 
proposed mechanism is not conclusive, it is thought hat it 
serves as a proton donor and also has a role in maintaining 
the correct electrostatic environment of the catalytic site 
[15]. 
2. Clinical presentation in McArdle's disease 
2.1. Symptomatology 
McArdle's disease is characterised by myalgia, severe 
cramps, early fatigue and muscle weakness brought on by 
exercise, although the severity of the symptoms does vary 
between individuals. Progressive weakness of the muscle 
may occur later in life. Patients are generally most affected 
by either high intensity exercise of short duration, such as 
sprinting or carrying heavy loads, or by less intense but 
sustained activity, such as walking uphill or riding a 
bicycle [16]. If exercise is continued once pain occurs, 
myoglobinuria may result and this can cause renal failure 
[17,18]. Symptoms are typically less severe during child- 
hood and as a consequence, the disease is often not 
recognised until individuals reach their second or third 
decade of life (Section 5.1). However, patients frequently 
recall incidences during childhood when they had prob- 
lems with exercise although, at the time, a clinical disorder 
was not suspected. 
2.2. The 'second wind' phenomenon 
Patients frequently find that they can continue to exer- 
cise with increased endurance if they rest briefly at the 
first signs of muscle pain. This is termed the 'second 
wind' phenomenon [19] and it is attributed to either a shift 
in a metabolic pathway or to a circulatory adjustment 
which results in enhanced peffusion of intramuscular capil- 
laries [19-21]. The metabolic shift is facilitated by mobili- 
sation of reserves, such as fatty acids [20,21]. This phe- 
nomenon has latterly been studied by 31P-NMR techniques 
[22,23] and it is clear, although not always feasible, that 
increasing the availability of substrate can improve exer- 
cise tolerance (Section 5.2). 
2.3. Clinical heterogeneity 
In addition to the normal clinical picture of McArdle's 
disease, a number of atypical presentations have been 
described. These include: a very mild form of the disease 
with symptoms such as excessive tiredness and poor 
stamina [16]; a late-onset form of the disease (> 40 years 
old) in which no exercise-induced symptoms were noted 
previously [24-27]; a fatal infantile form which is charac- 
terised by progressive weakness oon after birth and severe 
breathing difficulties followed by death before 4 months, 
as seen in two sisters [28,29]. An unrelated infant also 
exhibited this form of the disease but died at 16 days [30]; 
mild congenital weakness een in a 4 year old boy [31]; 
exercise-induced myoglobinuria n an 8 year old boy with 
no previous history of exercise intolerance [32]; an attack 
of myoglobinuria n a 42 year old man which was appar- 
ently unrelated to a triggering effect. The second episode 
of myoglobinuria resulted in severe renal failure [33]. 
2.4. Histology and the diagnosis of McArdle's disease 
McArdle's disease is typically diagnosed by negative 
histochemical staining for phosphorylase activity in a mus- 
cle biopsy [34]. This stain relies on the ability of phospho- 
rylase to work in the reverse direction and synthesise 
glycogen from glucose-l-phosphate -the newly formed 
glycogen is detected by an iodine stain. Added insulin, 
AMP (activators) and glycogen (primer) enhance the reac- 
tion to the extent hat even low levels of phosphorylase 
activity result in a deep blue stain. In the absence of 
phosphorylase activity, the section remains brown. In a 
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biopsy from McArdle's patients, the muscle fibres do not 
usually take up stain but the smooth muscle of the intra- 
muscular blood vessels does stain. In addition, McArdle's 
patients often show subsarcolemmal deposits of glycogen 
which can be detected with periodic acid-Schiff (PAS) 
stain on a portion of a muscle biopsy. These increases are 
typically 3-5-fold compared to the glycogen content of 
normal individuals. 
2.5. Exercise analysis 
tion is of limited use during intense exercise because the 
circulation cannot provide substrates (fatty acids and 
carbohydrates) and oxygen quickly enough to meet the 
energy demands [19]. Muscle glycogen phosphorylase 
breaks down glycogen to glucose-l-phosphate which en- 
ters the glycolytic pathway to generate ATP with the 
formation of pyruvate and, under anaerobic onditions, 
lactate. Use of glycogen for glycolysis instead of intra- 
cellular glucose results in greater net ATP generation and 
delays muscle fatigue [44]. 
Although histochemical staining of a muscle biopsy 
from patients is the most reliable method for the diagnosis 
of McArdle's disease (Section 2.4), the ischaemic forearm 
test may also be performed on patients. This test is based 
on the failure of blood lactate levels to rise in McArdle's 
disease in response to exercise (Section 1.1). However, this 
test is not specific for glycogen phosphorylase and may 
indicate a block in another enzyme of the glycolytic 
pathway. 
Muscle cell membrane damage frequently occurs in 
McArdle's patients due to over-exertion of the muscles 
and this releases intracellular components into the circula- 
tion. The most significant of these is myoglobin (Section 
2.1) but creatine kinase activity is almost always raised in 
the plasma of McArdle's patients. In addition to the release 
of these intracellular contents, acute local muscle damage 
appears as a painful hardening and shortening of the 
muscle. This contracture is electrically silent indicating 
that it is not caused by active contraction of the muscle 
fibres. It could be due to the same kind of failure of 
actin-myosin crossbridge relaxation as is known to occur 
in 'rigor mortis' when intramuscular ATP is depleted [35]. 
However, needle biopsy studies have shown that the mus- 
cle content of phosphocreatine is not depleted when the 
muscle is fatigued [36] and this has been confirmed by 
31P-NMR [37]. 
Leakage of potassium is also consequential to muscle 
damage. During whole body exercise, the large increases 
in the plasma potassium concentration offers a possible 
explanation of the cause of fatigue [38]. Induction of 
fatigue by electrical stimulation showed that muscle of a 
McArdle's patient was more fatiguable than that of a 
normal individual and this was attributed in part to 'fad- 
ing' of the muscle action potential [39-41] and partly to 
myofibrillar activation failure [42]. 
3. Glycogen utilisation in skeletal muscle 
3.1. Induction of glycogen breakdown during exercise 
3.2. Correlation of symptomatology with an absence of 
muscle glycogen phosphorylase 
Due to a lack of muscle phosphorylase activity, McAr- 
dle's patients cannot mobilise their muscle glycogen stores. 
Therefore, depletion of intracellular glucose and ATP, 
during the first few minutes of exercise, results in onset of 
symptoms. To exacerbate he situation, oxidative phospho- 
rylation is impaired in patients due to an abnormally low 
substrate flux through the TCA cycle. This is probably 
because the virtual absence of pyruvate from glycolysis is 
likely to reduce the rate of acetyl-CoA formation and this 
affects the TCA cycle [23,45]. Acetyl-CoA can be gener- 
ated from the breakdown of fatty acids but unless trained, 
most individuals have a limited capacity for fatty acid 
oxidation during exercise. This decline in oxidative phos- 
phorylation results in a decreased oxygen consumption i
patients [23] and in fact, maximal oxygen uptake into 
McArdle's muscle is 35-50% of normal values [46]. In 
addition, McArdle's patients exhibit a disproportionate 
increase in heart rate and ventilation rate compared to 
normal individuals [21,23]. 
3.3. Other biochemical effects of the glycogen block 
The absence of glycolysis and reduction in oxidative 
phosphorylation i McArdle's patients means that in- 
creased reliance is placed on the creatine kinase and 
adenylate kinase reactions. Both reactions regenerate ATP 
very rapidly to provide an immediate short-term source of 
energy [47]. The action of these enzymes in combination 
with decreased ATP generation from carbohydrate and 
fatty acids results in increased levels of ADP and AMP 
within the muscle. This affects normal metabolism of 
adenine nucleotides resulting in excessive purine degrada- 
tion [48,49]: 
ATP ~ ADP ",~ "" AMP - -~  ~ ~ Inosine ~ Hypoxanthine 
NH3 
In the resting state, fatty acid oxidation predominates in 
the skeletal muscle of normal individuals but during exer- 
cise, the energy requirements are largely met by glycogen 
breakdown and anaerobic glycolysis [43]. Aerobic oxida- 
Inosine, hypoxanthine and ammonia enter the blood- 
stream and elevated plasma levels of all three have been 
detected in some McArdle's patients following exercise 
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[48-50]. However, excessive release of hypoxanthine and 
inosine has not been observed in all McArdle's patients 
[51,52]. Elevated ammonia output is seen consistently but 
cannot be solely attributed to purine nucleotide degrada- 
tion use of amino acids as an alternative nergy source in 
McArdle's muscle also releases ammonia into the blood- 
stream (Section 5.2.). 
McArdle's patients also show an enhanced response to 
various hormones compared to normal individuals which 
helps to minimise the effect of the glycolytic block. Neural 
feedback from working muscle causes an increase in the 
concentrations of growth hormone, cortisol, noradrenaline, 
adrenaline and adrenocorticotrophic ormone and a de- 
crease in insulin concentration which results in mobilisa- 
tion of extramuscular fuel, such as glucose and free fatty 
acids, to meet the energy requirements of the muscle [53]. 
4. Molecular pathology of McArdle's disease 
4.1. Molecular phenotypes 
McArdle's disease is characterised by an absence of 
functional muscle glycogen phosphorylase but patients 
show heterogeneity in their protein and mRNA expression 
(Table 1). The majority of McArdle's patients do not have 
detectable muscle glycogen phosphorylase [54-61]; of 93 
patients, only 13 expressed low levels of protein [54,57-61] 
and a further two expressed inactive protein [55,61]. Of 22 
patients whose mRNA has been determined, twelve lacked 
detectable mRNA [54,57,59] whereas nine expressed the 
3.4 kb phosphorylase mRNA at normal [59,61] or reduced 
levels [56]. Another patient expressed a truncated form 
(1.2 kb) of the transcript [61]. Bidimensional protein maps 
of muscle extract from three McArdle's patients identified 
potential degradative intermediates of phosphorylase. Mus- 
cle phosphorylase (molecular mass 97 kDa) was not seen 
but two spots with molecular masses 60 kDa and 70 kDa 
were detected. However, these two spots were not recog- 
nised by antibodies to phosphorylase [62]. These spots may 
be completely unrelated to phosphorylase or alternately, 
the antibodies may have been sensitive to a conformational 
epitope that was altered by misfolding or by sample prepa- 
ration. 
4.2. Muscle glycogen phosphorylase g ne 
Although there have been a number of studies on the 
molecular phenotypes of McArdle's patients, until re- 
cently, nothing was known of the mutations causing the 
disease. The human muscle glycogen phosphorylase gene 
is approx. 14 kb [63]. Sequencing of the 5' region identi- 
fied several promoter regions [11] including a TATA-Iike 
homology, TTTAAA, located at position -29  (based on 
the designation of the transcription start site as + 1) and a 
potential CAAT box, CCAAGAC, at -80.  There is a 
region at -592  with the sequence CTCCAAAAGG which 
is necessary for efficient ranscription of the phosphorylase 
gene. This sequence superficially resembles the CArG 
motif CC(A/T)rGG present in the promoter egions of 
skeletal and cardiac muscle a-actin genes and has been 
implicated in their tissue-specific expression [64,65]. It is 
repeated at -252  in the 5' region of the phosphorylase 
gene, but expression studies indicate that this later se- 
quence is not necessary for transcription so sequence 
context may be critical [11]. 
Even before the elucidation of the mutations causing 
McArdle's disease, it was generally held to be an autoso- 
mal recessive disease [66,16]. Autosomal dominant inheri- 
tance was suggested in a family in which four generations 
were reportedly affected with McArdle's disease [67]. 
However, the disease was only confirmed in two individu- 
Table 1 
Molecular phenotypes in McArdle's patients 
Molecular phenotypes [54] [55] [56] [57] [58] [59] [60] [61 ] 
No protein, no mRNA 2 5 5 
No protein, normal mRNA 3 1 
No protein, decreased mRNA 3 
No protein, truncated mRNA 1 
No protein, mRNA n.d. 5 2 2 2 4 2 2 39 
Decreased protein, normal mRNA 1 1 
Decreased protein, mRNA n.d. 2 I 2 1 5 
Normal levels of inactive protein 1 1 
Total number of patients 9 3 10 3 6 11 3 48 
The column headings indicate the citations from which the information was obtained. 
n.d. = not determined. 
A number of studies have focused on expression of muscle phosphorylase protein and mRNA in McArdle's patients [54-61]. 
This has demonstrated the heterogeneity in the molecular phenotypes of patients with the same clinical condition. 
There is much more information available on the expression of phosphorylase protein than on mRNA expression. 
The majority of patients do not express protein at all but of those that do, the protein is generally present at very low levels. Normal levels of 
phosphorylase protein are seen in two patients but in both cases, the protein is inactive or virtually inactive [55-61]. 
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Mutation 
R49X 
77A->C 
122G->TT 
G204S 
L291P 
1606delG 
K542T 
1844+ 1G->A 
AF708/709 
Base change 
CGA->TGA 
ATG->CTG 
G->TT 
GGC->AGC 
CTG->CCG 
GAG->GA 
AAG->ACG 
G->A 
ATTC 
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1 
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13 
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'14' 
17 
Effect of mutation 
Nonsense 
Missense 
Frameshift 
Missense 
Missense 
Frameshift 
Missense 
Abnormal splicing 
Amino acid deletion 
Fig. 1. Sites of mutation and their detection in the muscle phosphorylase g ne. At present, here are nine known mutations across the muscle phosphorylase 
gene which cause McArdle's disease [71,72,74-77]. The rapid diagnosis of some of these mutations i facilitated by digestion of a PCR product with the 
restriction enzyme indicated. The G204S mutation disrupts a recognition site for HaelII but all the other mutations create an extra restriction site and so an 
additional band results from digestion with the enzyme. Rapid detection of 1844 + 1G --* A is dependent upon the introduction of a base change into the 
PCR product by a primer which binds adjacent to the possible site of mutation; in the presence of the mutation, the mismatch primer creates a recognition 
site for NcoI. The effects of each mutation are shown in the table. Note: Mutation 1844 + 1G ~ T has previously been defined as 1778de167 [109] but 
whilst a deletion of 67 bp in the transcript does result from this mutation, the primary defect is in fact alteration of the consensus splice site sequence and 
so the nomenclature has been reviewed. 
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als from two generations and a dominant mechanism of 
inheritance in this family is questionable. In most cases, 
heterozygous carriers for McArdle's disease are unaffected 
because it seems that one normal allele of the muscle 
phosphorylase gene is adequate for normal levels of the 
protein. However, there are a number of reports of mani- 
festing heterozygotes who do have phosphorylase activity 
upon histochemical staining but who show clinical symp- 
toms of McArdle's disease [68,69]. A threshold value of 
20-45% of normal has been suggested to be the minimum 
activity below which symptoms occur [69] although as- 
signment is tentative. 
4.3. Mutational analysis of McArdle's disease 
Initial work focused on restriction fragment length poly- 
morphism of the muscle phosphorylase gene of McArdle's 
patients but met with little success [56,61]. The muscle 
phosphorylase gene is notable for its lack of polymor- 
phisms and restriction enzyme analysis with 94 enzyme- 
probe combinations in 20 unrelated patients revealed just a 
single polymorphism at a CpG site associated with McAr- 
dle's disease [70]. This analysis did, however, preclude the 
possibility of gene deletions greater than 100 bp. 
Since these initial studies, sequencing has revealed a 
number of mutations in the muscle phosphorylase gene 
which cause McArdle's disease (Fig. 1). The most com- 
mon base change is a nonsense mutation [71,72], desig- 
nated R49X (nomenclature proposed in Ref. [73]). This 
results in premature termination of translation; the result- 
ing truncated peptide is so short that it is non-functional 
and probably rapidly degraded. A second mutation in exon 
1, 122G ~ TT, shifts the reading frame such that a short 
sequence of missense protein containing 11 amino acids is 
synthesised before translation is prematurely terminated 
[74]. Again the truncated peptide would probably be unsta- 
ble and therefore, rapidly degraded. 
There are four missense mutations and a single amino 
acid deletion which may have functional or structural 
consequences on muscle glycogen phosphorylase (Section 
4.4). The G204S mutation occurs in a domain involved in 
glycogen binding whereas K542T affects the glucose-bind- 
ing domain [72]. Both L291P and AF708/709 may alter 
normal protein folding and possibly, intracellular stability 
[75]. The initial methionine codon is altered by the 77A --* 
C mutation thus abolishing translation initiation [76]. An- 
other mutation (1844+ IG~A)  alters the consensus 
splice site sequence at the 5' end of intron 14 and as a 
consequence, an alternative sequence in exon 14 is used. 
This results in abnormal splicing which produces a 67 bp 
deletion in the transcript. The resulting shift in the reading 
frame generates a short sequence of missense polypeptide 
containing 14 amino acids before translation is prema- 
turely terminated after 580 amino acids [75]. Another 
frameshift is caused by the deletion of a single base in 
codon 509 (1606delG) and this again results in premature 
termination of translation, this time after 536 amino acids 
[77]. The allele frequencies of the above mutations are 
shown in Table 2. 
4.4. Effect of  mutations on molecular phenotypes 
The R49X mutation occurs in the coding region of the 
muscle phosphorylase gene and causes premature termina- 
tion of protein translation. However, of the patients whose 
biochemical phenotype is known, all those homozygous 
for the R49X mutation have no detectable mRNA on 
northern blots (Fig. 2). Therefore, premature termination of 
protein translation affects the stability of the mRNA [71,72] 
and there are a number of precedents for this in other 
N M5 M6 M2 N M7 N M8 M1 M3 M4 M9 N 
Mutation __+ R49X R49X R49X +_ R49X + R49X R49X n.d. Rg9X R49X + 
analysis + ? R49X R49X + R49X + ? 122G->TT ? R49X + 
3.4kb phosphorylase 
mRNA 
Key :  N = normal individual 
M1-9 = McArdle's patients [numbering as in ref. 71] 
+/+ = normal sequence i.e. no mutations 
n.d. = not determined 
Fig. 2. Comparison ofnorthern blot analysis and mutational nalysis. Northern blot analysis has shown heterogeneity in the expression ofphosphorylase 
mRNA in McArdle's patients [59]. Correlation of this information with the mutation analysis for these patients [71,74] shows that hose individuals who 
are homozygous for the R49 × mutation lack detectable mRNA. Therefore, a premature t rmination codon in the muscle phosphorylase g ne not only 
affects protein synthesis but decreases transcript s ability. However, detectable mRNA is seen with individual M1 although premature t rmination f
translation also occurs from both alleles in this individual. (Reprinted from 'McArdle's disease: molecular genetics and metabolic consequences of the 
phenotype' by R.J. Beynon et al. in Muscle and Nerve. Copyright: 1995, John Wiley and Sons, Inc.) 
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Table 2 
Allele frequency of the mutations causing McArdle's disease 
Mutation Allele frequency in Allele frequency in USA 
European population and Japanese population 
[71,74,109] [72,75-77] 
R49X 46 5 l 
77A ~ C 0 1 
122G ~ TT 1 n.d. 
G204S 2 8 
L291P 0 1 
1606delG n.d. 2 
K542T 0 3 
1844+1G ~ A 0 1 
AF708/709 n.d. 7 
n.d. = not determined. 
The most common mutation is R49X which is present in 46 out of a total 
of 76 available alleles from European McArdle's patients, The majority 
of these patients are Caucasians although there are a number of patients 
whose ethnic origins are not known. The USA patients are Caucasian and 
R49X is the predominant mutation in these patients. However, the 
AF708/709 mutation has only been found in Japanese patients (7 out of 
14 alleles) suggesting that this might be a common mutation in this 
population. None of the Japanese patients carry R49X and so, it would 
appear that McArdle's disease has occurred independently in these two 
populations. The other mutations are much less frequently observed. 
diseases. For example, decreased stability of the transcript 
in response to premature termination of translation occurs 
in human /3-globin mRNA as illustrated by the /30 thalas- 
saemias [78-81], mRNA of cystic fibrosis transmembrane 
conductance r gulator which is implicated in cystic fibro- 
sis [82] and mRNA of human /3-hexosaminidase A which 
is defective in Sandhoff disease [83]. 
Patient M 1 carries the R49X mutation on one allele of 
the muscle phosphorylase g ne and the 122G ~ TT on the 
other, both of which cause premature termination of trans- 
lation. However, this individual does seem to express low 
levels of mRNA as seen by northern blot analysis (Fig. 2) 
which is unexpected given that termination of translation 
in exon 1 occurs from both alleles. The mechanism by 
which mRNA stability could be differentially affected by 
these two different mutations i  not clear but it is possible 
that the mRNA carrying the frameshift mutation is not 
translatable. Degradation of aberrant transcripts i thought 
to be co-translational [84], such that a complete inability to 
translate the mRNA would cause it to have increased 
stability. 
Analysis of molecular phenotypes of patients has sug- 
gested that the missense mutations destabilise the protein 
[75]. Rabbit muscle glycogen phosphorylase r mains the 
only isozyme for which the three-dimensional structure has 
been determined and thus the structural interpretation of
amino acid changes must be based upon this protein. The 
overall amino acid sequence identity for rabbit and human 
muscle phosphorylase is 97% and there is no variation in 
any catalytic or allosteric sites [63,85]. All three of the 
G204S L29 IP 
I I 
Human muscle VHFYGHVEH Human muscle EGKELRLKQ 
Rabbit muscle VHFYGRVEH Rabbit muscle EGKELRLKQ 
Rat muscle VHFYORVEH Rat muscle EGKELRLKQ 
Human liver VHFYGKVEH Human liver EGKELRLKQ 
Rat liver VHFYGRVEH Rat liver EGKELRLKQ 
Human brain VHFYGRVEH Human brain EGKELRLKQ 
Rat brain VHFYORVEH Rat brain EGKELRLKQ 
Yeast VTFYGYVDR Yeast QGKELRLKQ 
Potato type H IRFFGHVEV Potato type H NGKLLRLKQ 
K542T AF'/08/709 
I I 
Human muscle KQENKLKFA Human muscle GEENFF IFG 
Rabbit muscle KQEN]KLKFA Rabbit muscle GEENFF IFG 
Rat muscle KQENKLKFS Rat muscle GEDNFF IFG 
Human liver KQENKLKFS Human liver GEENLF IFG 
Rat liver KQENKLKFS Rat liver GEENLF IFG 
Human brain KQENIKLKFS Human brain GAENLF IFG 
Rat brain KQENKLKFS Rat brain GEENLF IFG 
Yeast KLNNI~IRLV Yeast GEDNVFLFG 
Potato type H KMANKQRLA Potato type H GEDNFFLFG 
Fig. 3. Sequence conservation atthe sites of mutation in McArdle's disease. The above figure shows short segments of the amino acid sequence alignments 
for nine glycogen pbosphorylases [7] in the vicinity of the G204S, L291P, K542T and AF708/709 mutations. The mammalian sequences include liver, 
brain and muscle isozymes from human and rat plus the muscle isozyme from rabbit. Yeast phosphorylase and potato phosphorylase type H are shown to 
indicate the high degree of sequence conservation even in non-mammalian phosphorylases. All three missense mutations occur at a position at which there 
is absolute conservation of the amino acid between the nine sequences. Both pbenylalanine r sidues in the region 708/709 are highlighted, because the 
codons are the same and it is not possible to be more specific about he deletion. 
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missense mutations (G204S, L291P and K542T) change a 
highly conserved amino acid (Fig. 3). The sequence con- 
servation is such that the amino acid at these positions 
remains unchanged across the species [7] including two 
non-mammalian phosphorylases (yeast and potato type H). 
This suggests that each of these amino acids is critical for 
the normal function of glycogen phosphorylase; their alter- 
ation could decrease the activity or the stability of the 
mutant protein. There is also strong conservation i  the 
region of the AF708/709 mutation (Fig. 3). 
creased by heparin [21], noradrenaline [20,21] or by infu- 
sion of emulsified fat, particularly in combination with 
glucose [19]. The same effect was produced by fasting 
which increases plasma concentrations of free fatty acid 
[91]. However, a high fat diet gave more variable results 
because one patient reported no beneficial effect [89] 
whereas another noted subjective improvement after 3 
days although there was no increase in measured muscle 
strength [92]. The benefits of a high fat intake on muscle 
performance must be weighed up against the potentially 
detrimental effect on an individual's long-term health. 
5. Clinical management and therapy 
5.1. Exercise management 
Exercise management and weight control have an im- 
portant role to play in the management of McArdle's 
disease. Weight determines oxygen consumption during 
walking, especially when walking uphill. It is therefore 
advantageous for a patient with McArdle's disease to 
avoid excess weight. Patients hould also try to keep active 
within the capability of their muscles as reduced activity in 
patients with muscle disorders can diminish the mitochon- 
drial function in muscle [86]. The greater the mitochondrial 
oxidative capacity, the less dependent an individual is on 
glycogenolysis. Children are more active than adults with a 
higher aerobic capacity per kilogram body weight [87] and 
this may explain why McArdle's disease is usually not 
diagnosed in young children. 
5.2. Dietary management 
The aim of any current herapy for McArdle's disease is 
to enable patients to exercise with increased tolerance and 
to prevent the occurrence of muscle damage or myoglobin- 
uria which can lead to renal failure. The provision of 
alternative or additional energy fuels to the skeletal muscle 
can accelerate the onset of the 'second wind' phenomenon 
and thus alleviate glycolytic deprivation. 
Carbohydrate supplementation 
Glucose infusion enables patients to exercise with in- 
creased endurance [19,21,22,50] and prevents exercise-in- 
duced ATP degradation as measured by a decrease in the 
degradative metabolites [50] and by a decline in plasma 
ammonia [23]. Similarly, fructose infusion improves exer- 
cise endurance [ 19,21 ]. However, long-term oral adminis- 
tration of glucose or fructose has been largely unsuccessful 
in improving the exercise capabilities of patients [16,89]. 
Benefits are only seen when carbohydrate is given immedi- 
ately before exercise and in practice, it is not always 
possible to predict a bout of exertion [90]. 
Fatty acid supplementation 
McArdle's patients could exercise with increased en- 
durance when plasma levels of free fatty acid were in- 
Amino acid/protein supplementation 
There is evidence for increased utilisation of amino 
acids in skeletal muscle of McArdle's patients [52,93]. 
Therefore, provision of adequate amino acids by direct 
supplementation, r via a high protein diet might improve 
muscle function. This was confirmed in one patient whose 
protein intake was increased to 25-30% protein from 14% 
[94]. In a subsequent s udy, three patients were provided 
with branched chain amino acids in amounts calculated to 
exceed the levels expected from a high protein diet but 
none experienced either an immediate or long-term (1-2 
months) subjective improvement or an objective benefit as 
assessed by their maximal strength and endurance [95]. 
The first step in amino acid catabolism is donation of 
the a-amino group to 2-oxoglutarate (a TCA cycle inter- 
mediate) in a transamination reaction which generates the 
cognate 2-oxo acid and glutamate. The 2-oxoglutarate may 
be regenerated by deamination with the release of ammo- 
nia. Alternately, a second transamination reaction with 
pyruvate regenerates 2-oxoglutarate and results in the cor- 
responding formation of alanine. In the normal individual, 
alanine and glutamine (formed by the reaction of gluta- 
mate with ammonia) provide a mechanism for the elimina- 
tion of nitrogen from the muscle and its transport to the 
liver for detoxification. However, in McArdle's disease, 
the supply of precursors for alanine and glutamine is 
compromised. In exercising McArdle's muscle, glycolytic 
flux is suppressed and it is unlikely that adequate pyruvate 
is synthesised to sustain the levels of alanine required for 
ammonia removal. Likewise, any reaction that drains TCA 
cycle intermediates, uch as 2-oxoglutarate, would ulti- 
mately impair energy metabolism. Thus, a decreased abil- 
ity to remove ammonia, in the form of alanine and glu- 
tamine might explain the elevated plasma ammonia levels 
during exercise in McArdle's disease [38]. These increased 
ammonia levels may be responsible in part for the muscle 
pain and fatigue [96]. The ability of glucose to diminish 
ammonia output by McArdle's muscle [23] is probably due 
to an increased supply of pyruvate which can be transami- 
nated to alanine. 
Uptake and oxidation of the branched chain amino acids 
occurs in both normal individuals and at a higher rate in 
McArdle's patients during exercise [52]. Consistent with 
this suggestion is the observation of exercise-induced acti- 
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vation of the branched chain 2-oxo acid dehydrogenase, 
the key enzyme in the oxidation of branched chain amino 
acids [97]. The complex was activated to a greater extent, 
and at a lower work load in McArdle's patients compared 
to normal individuals. Amino acid supplements (10 g each 
of leucine, isoleucine and valine) were initially given to 
patients prior to exercise in an effort to improve their 
performance. However, supplementation did not have the 
expected beneficial effect and in fact, exercise perfor- 
mance actually deteriorated [96]. This may be due to the 
increased ammonia resulting from transamination of these 
amino acids. Any benefits gained from branched chain 
amino acid oxidation must be offset against he additional 
nitrogen burden. 
In contrast, supplements of 10 g of the ornithine salts of 
the 2-oxo acids of leucine and valine (4-methyl-2-oxopen- 
tanoate and 3-methyl-2-oxobutanoate, respectively) and 5 
g of the sodium salt of the 2-oxo acid of isoleucine 
(3-methyl-2-oxopentanoate), if given 20 min prior to exer- 
cise, improved exercise performance, resulted in smaller 
increases in heart rate and suppressed plasma ammonia 
output [38,96]. The 2-oxo acids provide an alternative 
energy source but they do not contribute to the nitrogen 
load of the muscle cells, sparing pyruvate and 2-oxogluta- 
rate. If the supplements of 2-oxo acids were given 90 min 
prior to exercise, this beneficial effect was no longer seen 
[52] which may have been due to re-amination. The most 
consistent increase in endurance was achieved when the 
branched chain oxo acids were combined with 75 g glu- 
cose given orally 30 rain before exercise [38,96]. 
Uptake of alanine by exercising muscle was described 
in one McArdle's patient [93] although it is usually re- 
leased from normal muscle. A later study with a number of 
McArdle's patients initially appeared to be at variance 
with this finding as alanine was released by muscle [52]. 
However, when the exercise protocols were examined in 
more detail, the two opposing results can be related to the 
work pattern (Fig. 4a). In both studies, similar total work 
was performed but in the earlier study, the work was 
gradually increased and so, it is likely that the patient 
actually reached the 'second wind'. It is possible to gain 
some insight into alanine metabolism by combining the 
information from these two studies although the conclu- 
sions should be treated with caution (Fig. 4b). Release of 
alanine from exercising McArdle's muscle peaks earlier, 
and total alanine output is lower than in normal individu- 
als. This is consistent with an initially increased emand 
on pyruvate for transamination and a subsequent decrease 
in the pyruvate pool which cannot be replenished. It then 
appears that McArdle's muscle actually takes up alanine 
which may be driven by gluconeogenesis. However, the 
magnitude of alanine uptake into muscle is substantially 
lower than initial release. 
Amino acid supplementation may have a second effect 
on muscle protein metabolism. Increased oxidation of 
amino acids by skeletal muscle in McArdle's disease 
a) 
8O 
6O 
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g' 20 
0 
0 20 40 60 80 
Exercise duration (rain) 
b) 
160 
120 ~ Release 
80 
~ 40 II 
0 2 ~40 60-  80 
-40 - Time (rain) = 
~ -80 - 
-120 + 
Uptake 
- 160  l 
Fig. 4. Alanine fluxes in McArdle's disease. This figure collates the data 
from two studies on alanine flux in McArdle's disease. They used very 
different exercise protocols, which are illustrated inpanel a. The study by 
Wagenmakers and colleagues ( tudy I) [52] used short periods of higher 
intensity exercise, whereas that of Wahren and colleagues ( tudy II) [93] 
was a longer duration, low intensity programme. The comparisons of the 
two protocols are approximate, and are based on our interpretation f the 
experimental details given. The data for alanine flux, obtained from both 
studies (including those from normal individuals), are placed on the same 
time scale, but must be interpreted in the light of the different exercise 
protocols. McArdle's patients, []; Normal individuals, I .  
might reduce their availability for the synthesis of new 
muscle protein [98] or elicit enhanced protein degradation. 
If this imbalance in protein turnover is prolonged it could 
ultimately lead to long term muscle wasting and weakness. 
Vitamin B-6 supplementation 
Glycogen phosphorylase r quires PLP as a cofactor and 
apo-phosphorylase cannot be detected in skeletal muscle 
[99]. It is not clear whether this is due to a marked 
instability of apo-enzyme or whether the apo-enzyme has 
such a high affinity for its cofactor that it 'scavenges' PLP 
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from other body pools. However, because phosphorylase is 
such an abundant protein (2-5% of the total soluble 
protein in skeletal muscle), and because of the large mass 
of the musculature, 80% of the body pool of vitamin B-6 is 
attached to this enzyme [100]. We have used [G-3H] 
pyridoxine as a specific label for phosphorylase in vivo 
and have observed that the rate of loss of labelled PLP 
from the enzyme parallels the rate of phosphorylase d gra- 
dation [101-103]. Therefore, release of PLP from 
phosphorylase is dependent on degradation of the protein 
[104]. Vitamin B-6 metabolism studies have consistently 
identified a large, slowly accessible vitamin B-6 pool in 
the body [105,106] which is undoubtedly muscle glycogen 
phosphorylase. The other body pools of vitamin B-6 ap- 
pear to have a much higher turnover rate and are probably 
more readily depleted when vitamin B-6 intake is inade- 
quate. In contrast, even extended periods of vitamin B-6 
deprivation do not significantly diminish the adult muscle 
phosphorylase pool [107,108]. This has led to the sugges- 
tion that the daily vitamin B-6 requirements are different 
in growth and maintenance; during growth, vitamin B-6 is 
incorporated into the slow muscle phosphorylase pool, 
whereas in the adult, the daily requirement is that which is 
needed to sustain the fast pools [106]. We therefore pro- 
pose that muscle phosphorylase could function as a 
'buffer', compensating for day-to-day variation in dietary 
intake of vitamin B-6 in normal individuals. 
The majority of McArdle's patients lack muscle glyco- 
gen phosphorylase, which means that this slow pool of 
vitamin B-6 is absent and consequently, its 'buffering' 
capacity is lost. McArdle's patients may therefore be more 
reliant on a regular intake of vitamin B-6 and vitamin B-6 
status, as assessed by an erthyrocyte transaminase assay, 
does seem to be compromised in some of our patients 
[109]. Furthermore, McArdle's patients may be more re- 
liant on adequate vitamin B-6 compared to normal individ- 
uals because they are dependent on alternative nergy 
pathways which require PLP. Aminotransferases play a 
key role in amino acid catabolism (Section 5.2.) and these 
enzymes are PLP-dependent. In addition, there is evidence 
that carnitine biosynthesis requires PLP. Carnitine is re- 
quired to facilitate the transport of fatty acyI-CoA across 
the inner mitochondrial membrane prior to oxidation. Inad- 
equate vitamin B-6 status results in reduced carnitine 
biosynthesis and as a consequence, reduced fatty acid 
oxidation [110]. 
We have postulated that the exercise performance of 
those McArdle's patients who lack glycogen phospho- 
rylase protein might be improved by supplementation with 
relatively high daily doses (50 mg) of vitamin B-6 (the 
recommended daily dose for normal individuals is 2 mg). 
Vitamin B-6 supplementation did improve the muscle fa- 
tiguability of three McArdle's patients by increasing the 
force generation of the muscle [109]. This implies that 
improvement is due to an increase in fuel 
mobilisation/utilisation and the inference from this is that 
the cofactor saturation of the aminotransferases in the 
muscles is improved. Supplementation f two patients with 
vitamin B-6 in earlier studies did not prove effective 
[ 18,11 1 ], but both patients had some phosphorylase protein 
on an SDS polyacrylamide gel. The presence of protein, 
albeit inactive, means that it could still function as a 
'buffer' for PLP and vitamin B-6 supplementation may not 
be beneficial in these patients. Mild sensory neuropathy 
associated with vitamin B-6 overdosage is only seen at 
levels of 2-4 g /d  over several months [112]. Therefore, 
vitamin B-6 at 50 mg/d may potentially improve the 
exercise capacity of the majority of McArdle's patients 
without having a detrimental effect on their health. In 
addition, as aminotransferases r quire PLP as a cofactor, 
we suggest hat any increased protein or amino acid regi- 
men must ensure that vitamin B-6 intake is adequate. If the 
activity of the aminotransferases is limited by inadequate 
PLP then the increased protein may have little benefit. 
5.3. Gene therapy 
Interest is now being focused on gene therapy in the 
treatment of genetically inherited iseases. A recombinant 
adenovims has been used to drive expression of rabbit 
muscle phosphorylase cDNA in a C2C12 myoblast cell 
line [1 13]. Adenoviral delivery into myoblasts, which were 
subsequently induced to differentiate, resulted in a moder- 
ate and transient increase in phosphorylase activity. How- 
ever, introduction i to non-proliferating myotubes resulted 
in higher phosphorylase activity which was sustained over 
the period of the experiment (20 days). The heterologously 
expressed phosphorylase was subject o both hormonal and 
allosteric ontrol which suggests that glycogen breakdown 
will occur in a regulated manner in the treated muscle of 
patients. It might be anticipated that when suitable delivery 
vehicles are developed for muscle, probably driven by 
other severe myopathies, uch therapy in McArdle's dis- 
ease will also be successful. 
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